Toronto, Ontario — (Newsfile Corp. – September 26, 2023) – Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (“Cardiol” or “companyDavid Elsley, President and CEO of Cardiol, Inc., a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. announced that he would be giving a presentation about his company. Today’s brief will be broadcast live at the Cantor Fitzgerald 2023 Global Healthcare Conference at the InterContinental New York Berkeley Hotel on September 26, 2023 at 4:55 PM ET.

date: Tuesday, September 26, 2023
time: 4:55 p.m. (ET)
Live video webcast link: www.wsw.com/webcast/cantor19/crdl/2077845

A replay of the presentation can be accessed on our website under section www.cardiolrx.com/investors/events-presentations/.

About Cardiol Therapeutics

Cardiol Therapeutics Co., Ltd. (NASDAQ: CRDL) (TSX: CRDL) is a clinical-stage life sciences company focused on research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company’s lead small molecule drug candidate, CardiolRx™ (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. Cannabidiol inhibits activation of the inflammasome pathway, an intracellular process known to play a key role in the development and progression of inflammation and fibrosis associated with myocarditis, pericarditis, and heart failure. It is recognized that

Cardiol has received an Investigational New Drug Application from the U.S. Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx™ in two diseases that affect the heart. (i) Recurrent pericarditis (MAvERIC pilot study; NCT05494788), a phase II multicenter, open-label pilot study, is an inflammatory disease of the pericardium with symptoms such as debilitating chest pain, shortness of breath, and fatigue; leading to physical limitations, decreased quality of life, and emergency room visits. , and was hospitalized. (ii) A Phase II, multinational, randomized, double-blind, placebo-controlled trial of acute myocarditis, an important cause of acute and fulminant heart failure and the leading cause of sudden death in young adults (ARCHER Study; NCT05180240) Cardiac death in people under 35 years of age.

Cardiol is also developing a new subcutaneous formulation of cannabidiol for use in heart failure, which is the leading cause of death and hospitalization in developed countries, and associated healthcare costs exceed $30 billion annually in the United States. We also do

For more information about Cardiol Therapeutics, please visit cardiolrx.com.

Cautionary Note Regarding Forward-Looking Information:

This news release contains “forward-looking information” within the meaning of applicable securities laws. All statements, other than statements of historical fact, that refer to Cardiol’s activities, events, or developments that will occur, may occur, are likely to occur, or are anticipated to occur in the future are “forward-looking information.” is. Forward-looking information contained herein may include statements regarding our focus on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, the molecular targets and mechanisms of action of our product candidates; Yes, but not limited to: the Company’s intended clinical research and trial activities and timelines associated with such activities and the Company’s plans to advance the development of novel subcutaneous formulations of CardiolRx™ for use in heart failure; The forward-looking information contained herein reflects Cardiol’s current expectations and beliefs based on information currently available, is based on certain assumptions and is subject to various factors that may cause actual events to occur. are subject to known and unknown risks, uncertainties and other factors. or that results may differ materially from any future results, performance or achievements expressed or implied by forward-looking information and are not (and should not be considered) guarantees of future performance. . These risks and uncertainties and other factors include those discussed in the Company’s Annual Report on Form 20-F dated March 28, 2023, as well as product commercialization and clinical studies. involves risks and uncertainties associated with. These assumptions, risks, uncertainties and other factors should be considered carefully and investors should not place undue reliance on forward-looking information and should not rely on such information for other purposes. may not be appropriate. Any forward-looking information speaks only as of the date of this press release and, except as required by applicable securities laws, Cardiol does not believe that any future forward-looking information, whether as a result of new information or otherwise, We disclaim any intention or obligation to update or revise any forward-looking information. , future events, results or otherwise.

For more information, please contact us below.

Trevor Burns, Investor Relations +1-289-910-0855
trevor.burns@cardiolrx.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/181851.